Raccagni Angelo Roberto, Galli Laura, Spagnuolo Vincenzo, Bruzzesi Elena, Muccini Camilla, Bossolasco Simona, Ranzenigo Martina, Gianotti Nicola, Lolatto Riccardo, Castagna Antonella, Nozza Silvia
From the Vita-Salute San Raffaele University.
Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy.
Sex Transm Dis. 2023 May 1;50(5):247-251. doi: 10.1097/OLQ.0000000000001771. Epub 2023 Jan 13.
We assessed the vaccination effectiveness (VE) of multicomponent meningococcal serogroup B (4CMenB) vaccine against gonorrhea among people living with HIV (PLWH) with a previous diagnosis of sexually transmitted infection.
Unmatched case-control study on men who have sex with men living with HIV, in care at San Raffaele Scientific Institute, Milan, Italy, with gonorrhea, syphilis, chlamydia, or anal human papillomavirus between July 2016 (beginning of 4CMenB vaccination) and February 2021 (date of freezing). For the analysis, cases were people with ≥1 gonorrhea infection since July 2016, and controls were people with ≥1 syphilis, chlamydia, or anal human papillomavirus infection since July 2016. Logistic regression was used to provide the estimate of 4CMenB VE against gonorrhea.
Included people living with HIV were 1051 (103 cases, 948 controls); 349 of 1051 (33%) received 2 doses of 4CMenB vaccination. The median follow-up was 3.8 years (2.1-4.3 years). The unadjusted estimate for VE against gonorrhea was 42% (95% confidence interval, 6%-64%; P = 0.027). Logistic regression showed that VE against gonorrhea remained significant (44%; 95% confidence interval, 9%-65%; P = 0.020) after adjusting for some factors that might have a potential influence on VE or those with significant unbalanced distributions between cases and controls at univariable analysis.
4CMenB vaccination is associated with a lower risk of gonorrhea in the setting of men who have sex with men living with HIV with a previous sexually transmitted infection.
我们评估了多组分B群脑膜炎球菌疫苗（4CMenB）对既往有性传播感染诊断的HIV感染者（PLWH）预防淋病的疫苗效力（VE）。
对2016年7月（4CMenB疫苗接种开始）至2021年2月（数据冻结日期）期间在意大利米兰圣拉斐尔科学研究所接受治疗的男男性行为HIV感染者进行非匹配病例对照研究，这些感染者患有淋病、梅毒、衣原体感染或肛门人乳头瘤病毒感染。分析时，病例为自2016年7月以来至少有1次淋病感染的人，对照为自2016年7月以来至少有1次梅毒、衣原体或肛门人乳头瘤病毒感染的人。采用逻辑回归分析来估计4CMenB疫苗预防淋病的效力。
纳入的HIV感染者有1051人（103例病例，948例对照）；1051人中有349人（33%）接种了2剂4CMenB疫苗。中位随访时间为3.8年（2.1 - 4.3年）。未调整的预防淋病效力估计值为42%（95%置信区间，6% - 64%；P = 0.027）。逻辑回归分析显示，在对一些可能对效力有潜在影响或在单变量分析中病例与对照之间分布显著不均衡的因素进行调整后，预防淋病的效力仍然显著（44%；95%置信区间，9% - 65%；P = 0.020）。
在既往有性传播感染的男男性行为HIV感染者中，接种4CMenB疫苗与淋病风险降低相关。
